Weight Loss with GLP-1s in Everyday Care: Vanderbilt Study Shows Gaps vs. Clinical Trials
Michael Albert, Co-Founder, Chief Medical Officer at Accomplish Health posted on X:
”Real-World GLP-1 Data: Vanderbilt Obesity Clinic Study (n=2,306)
Clinical trials showed 15–21% weight loss with semaglutide and tirzepatide. But how do patients actually fare in practice?
Key Findings:
Median treatment duration: 10.7 months (50% discontinued by 12 months)
Only 23% reached semaglutide 2.4 mg, 28% reached tirzepatide 15 mg
Weight loss for those who continued treatment:
• 6 months: –9.4%
• 12 months: –14.4%
13.6% had medication-related ER visits (mostly GI side effects)
Context:
This was not a typical setting—patients had multidisciplinary support and NO-COST medication access through employer insurance bundles.
Reality Check:
– With the right care model, real-world outcomes can approach RCTs
– Most patients never reach target doses
– Half stop treatment within a year
The gap between “can work” and “does work” remains large. Sustained success appears tied to comprehensive care models that most patients can’t easily access.”
Read the full study here.
Stay updated with Hemostasis Today.
-
Jan 14, 2026, 11:38Khokon Miah Akanda Shares A major 4-Guideline Comparison on BP Management in Stroke
-
Jan 14, 2026, 11:26Pablo Albasanz-García and Colleagues on Anticancer Treatment-Induced Arterial and Venous Thrombosis
-
Jan 14, 2026, 11:16ISTH 2026: Laurent Bertoletti To Serve as Vice Theme Leader for VTE
-
Jan 14, 2026, 11:08Leni von Bonsdorff Invites You to Hear and Learn The Latest News in The Plasma Field
-
Jan 14, 2026, 05:56Arun V J on The “Whole Blood” Nostalgia Trap
-
Jan 13, 2026, 16:38Caitlin Raymond: Understanding TAMOF as a TTP-Like Process
-
Jan 13, 2026, 15:22John Amako: Childhood to Adulthood Management Approach for SCD
-
Jan 13, 2026, 13:03Claudio Laudani on Dual Versus Single Antiplatelet Therapy
-
Jan 13, 2026, 12:46Stephanie Carlin and Colleagues on Clinical Outcomes of DOAC-Anticonvulsant Coprescription